

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 1 of 2</p>	ATTORNEY DOCKET No.	SERIAL No.
	8674-000026	10/727,911
	APPLICANT	
	Maxime Lampilas et al.	
	FILING DATE	GROUP
	December 4, 2003	1624

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.						

FOREIGN PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
1.						

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)						
Ref. Desig.	Examiner's Initials					
1.		Booker-Milburn, K.I. et al., "Azabenzocycloheptenones. Part 20. Synthesis and utilisation of 4-amino-1,2,3,4-tetrahydro-1(1H)-benzazepines," J. Chem. Soc., Perkin Trans. 1: Organic and Bio-Organic Chemistry, pp. 3261-3273 (1997).				
2.		Elliott, R. et al., "Syntheses and stereochemistry of 4-hydroxy tetrahydroisoquinolines in the 1-benzyl and 1-phenethyl series. Efficient routes to isopavines and homoisopavines," Tetrahedron Letters, Vol. 21, pp. 4633-4636 (1980).				
3.		Heier, R.F. et al., "An asymmetric synthesis of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo-[4,5,1-ij]quinolin-2(1H)-one and its [2-14C]- and [6,7-3H2]-labeled forms," CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (1997).				
4.		Heier, R.F. et al., "Synthesis and Biological Activities of (R)-5,6-Dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and Its Metabolites," J. Med. Chem., Vol. 40, pp. 639-646 (1997).				
5.		Masumoto, S. et al., "Preparation of tricyclic quinazolinones as poly (ADP-ribose) polymerase inhibitors," CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (2001).				
6.		Moon, M.W. et al., "Dopaminergic and Serotonergic Activities of Imidazoquinolinones and Related Compounds," J. Med. Chem., Vol. 35, pp. 1076-1092 (1992).				
7.		Moon, M.W. et al., "Medicinal chemistry of imidazoquinolinone dopamine receptor agonists," CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (1994).				

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 2 of 2	ATTORNEY DOCKET NO.	SERIAL NO.
	8674-000026	10/727,911
	APPLICANT	
	Maxime Lampilas et al.	
	FILING DATE	GROUP
	December 4, 2003	1624

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
8.		Moon, M.W. et al., "Synthesis of tritium-labeled (R)-5-(di[2,3-3H ₂]propylamino)-5,6-dihydro-4H-imidazo-[4,5,1-ij]quinolin-2(1H)-one([3H]U-86170) and (R)-5-([2,3-3H ₂]propylamino)-5,6-dihydro-4H-imidazo-[4,5,1-ij]quinolin-2(1H)-one([3H]U-91356)," CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (1993).
9.		Nagasaka, T. et al., "Preparation of 1,4-dihydro-4-phenyl-3,5-pyridinedicarboxylic acids as calcium antagonists," CAPLUS Database, Chemical Abstracts Service, Columbus, Ohio (1994).
10.		Romero, A.G. et al., "Oxidative Cyclization of Acyclic Ureas with Bis(trifluoroacetoxy)iodobenzene to Generate N-Substituted 2-Benzimidazolinones," Tetrahedron Letters, Vol. 37, No. 14, pp. 2361-2364 (1996).
11.		Tirk, I. et al., "Hydroxyiminoisoquinolin-3(2H)-Ones, VI: Synthesis and Biological Activity of Some Aminoisoquinoline Derivatives," Acto Chimica Hungarica, Vol. 124, No. 2, pp. 195-207 (1987).
12.		Zhou, B. et al., "Studies Directed to the Total Synthesis of ET 743 and Analogues Thereof: An Expeditious Route to the ABFGH Subunit," Org. Lett., Vol. 4, No. 1, pp. 43-46 (2002).

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.